Cargando…

Effect of sodium–glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus

BACKGROUND: Asprosin, a novel adipokine that raises glucose levels and stimulates appetite, has been proved to be pathologically increased in populations predisposed to type 2 diabetes mellitus (T2DM), obesity, and cardiovascular diseases. The mechanisms of sodium-glucose co-transporter-2 (SGLT2) in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Aijun, Feng, Zhanrong, Yuan, Lu, Zhang, Ying, Li, Qian, She, Yuqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992350/ https://www.ncbi.nlm.nih.gov/pubmed/33766125 http://dx.doi.org/10.1186/s13098-021-00652-5

Ejemplares similares

Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus
por: Zhang, Xinyue, et al.
Publicado: (2019)

Safety and effectiveness of the sodium‐glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus
por: Hadd, Michael J., et al.
Publicado: (2023)

Sensitive asprosin detection in clinical samples reveals serum/saliva correlation and indicates cartilage as source for serum asprosin
por: Morcos, Yousef A. T., et al.
Publicado: (2022)

Serum concentration of asprosin in new-onset type 2 diabetes
por: Naiemian, Shakiba, et al.
Publicado: (2020)

Increased serum asprosin is correlated with diabetic nephropathy
por: Wang, Rui, et al.
Publicado: (2021)

The Asprosin–OLFR734 module regulates appetitive behaviors
por: Liu, Yang, et al.
Publicado: (2020)

Cardiovascular Effects of Sodium Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus
por: Kumar, Surender, et al.
Publicado: (2019)

Sodium-Glucose Co-Transporter 2 Inhibitors Reduce Macular Edema in Patients with Diabetes mellitus
por: Tatsumi, Tomoaki, et al.
Publicado: (2022)

Serum Asprosin Correlates with Indirect Insulin Resistance Indices
por: Mirr, Małgorzata, et al.
Publicado: (2023)

Association Between Plasma Asprosin Levels and Gestational Diabetes Mellitus
por: Boz, İbrahim Bekir, et al.
Publicado: (2023)

The Asprosin-OLFR734 hormonal signaling axis modulates male fertility
por: Wei, Fangchao, et al.
Publicado: (2019)

Serum levels of Asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study
por: Moradi, Nariman, et al.
Publicado: (2021)

Asprosin in pregnancy and childhood
por: Janoschek, Ruth, et al.
Publicado: (2020)

Association Between Serum Asprosin and Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus in the Community: A Cross-Sectional Study
por: Xu, Linxin, et al.
Publicado: (2022)

The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus
por: Brunton, S. A.
Publicado: (2015)

Sodium‐glucose co‐transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician
por: Dandona, Paresh, et al.
Publicado: (2017)

Meal-Related Asprosin Serum Levels Are Affected by Insulin Resistance and Impaired Fasting Glucose in Children With Obesity
por: Corica, Domenico, et al.
Publicado: (2022)

Real-World Effectiveness of Sodium Glucose Co-Transporter-2 Inhibitors in Japanese Patients with Diabetes Mellitus
por: Ito, Yuichiro, et al.
Publicado: (2019)

Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus
por: Alkagiet, Stelina, et al.
Publicado: (2020)

High Serum Asprosin Levels Are Associated with Presence of Metabolic Syndrome
por: Hong, Tao, et al.
Publicado: (2021)

Medication counselling with sodium glucose transporter 2 inhibitor therapy
por: Kalra, Sanjay, et al.
Publicado: (2014)

Harms and benefits of sodium-glucose co-transporter 2 inhibitors
por: Chesterman, Thomas, et al.
Publicado: (2020)

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
por: Erythropoulou-Kaltsidou, Anastasia, et al.
Publicado: (2019)

Sodium-glucose co-transporter 2 inhibitors beyond diabetes
por: Williams, Dimity L, et al.
Publicado: (2022)

Sodium glucose co-transport 2 inhibitors for gout treatment
por: Somagutta, Manoj Kumar Reddy, et al.
Publicado: (2022)

Renal safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus
por: Desai, Mehul, et al.
Publicado: (2017)

The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus
por: Evans, Marc, et al.
Publicado: (2022)

Low Serum Cartonectin/CTRP3 Concentrations in Newly Diagnosed Type 2 Diabetes Mellitus: In Vivo Regulation of Cartonectin by Glucose
por: Ban, Bo, et al.
Publicado: (2014)

Clinical And Biochemical Outcomes Of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors In Type 2 Diabetes Mellitus Patients
por: Saleem, Muhammad, et al.
Publicado: (2021)

Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus
por: Geist, Barbara Katharina, et al.
Publicado: (2023)

Eligibility of sodium–glucose co‐transporter‐2 inhibitors among patients with diabetes mellitus admitted for heart failure
por: Sharma, Abhinav, et al.
Publicado: (2019)

A novel strategy for the treatment of diabetes mellitus - sodium glucose co-transport inhibitors
por: Niazi, Asfandyar Khan, et al.
Publicado: (2010)

The Factors Influencing the Renal Glucose Threshold in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Cui, Shan-Shan, et al.
Publicado: (2021)

Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus
por: Bays, Harold
Publicado: (2013)

The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients
por: Chang, Chia Lin, et al.
Publicado: (2019)

Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes
por: Mudaliar, Sunder, et al.
Publicado: (2012)

Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
por: D'Onofrio, Nunzia, et al.
Publicado: (2021)

Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease
por: Zanoli, L., et al.
Publicado: (2015)

The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure
por: Fadiran, Olusayo, et al.
Publicado: (2021)

Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection
por: Wu, Victor Chien-Chia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4srrqpshri25qofvmm9qnhaf1h